The Doctor on Your Wrist Gets a Clinical-Grade Upgrade

BELFAST, Northern Ireland & NEUCHÂTEL, Switzerland – July 28, 2026 – For years, the wearable on your wrist has been a faithful companion for counting steps, tracking sleep, and logging workouts. Recently, it has graduated to a more serious role, offering glimpses into our cardiovascular health. Now, that evolution is taking a significant leap forward. A new partnership between biosensing expert B-Secur and Swiss technology innovator CSEM aims to elevate health wearables from wellness trackers to clinically-validated monitoring devices, potentially changing how we manage heart health.

The collaboration combines two powerful heart-sensing technologies—photoplethysmography (PPG) and electrocardiogram (ECG)—into a single, integrated solution for device manufacturers. By merging CSEM’s deep expertise in PPG with B-Secur’s FDA-cleared ECG analytics, the partnership promises to equip a new generation of wearables with the accuracy and reliability once confined to a hospital setting.

The Synergy of Sensing: Combining PPG and ECG

Most of today's popular smartwatches and fitness bands rely on PPG technology. This method uses light-based sensors to measure blood volume changes in your wrist, providing continuous data on heart rate and blood oxygen levels. It’s an effective tool for round-the-clock monitoring and can flag an irregular pulse. However, its diagnostic power has limits. While PPG can suggest a problem, it often struggles to accurately classify specific types of arrhythmia beyond atrial fibrillation (AFib), a distinction critical for determining clinical risk and treatment.

This is where ECG technology becomes indispensable. As the recognized gold standard in cardiology, an ECG measures the heart's electrical activity directly, providing the detailed, high-fidelity data needed to diagnose complex rhythm disorders like tachycardias and premature ventricular contractions (PVCs). The challenge has been making this clinical-grade tool accessible and reliable in a consumer device.

The partnership between B-Secur and CSEM addresses this by creating a powerful tandem. In their model, CSEM’s PPG technology acts as the vigilant, always-on sentinel, continuously screening for irregularities in the background. When it detects a potential issue, B-Secur’s FDA-cleared ECG algorithms can be activated to perform a high-confidence analysis, confirming or ruling out a specific condition. It’s a two-tiered system that balances continuous, low-power monitoring with on-demand clinical precision.

“By combining CSEM’s expertise in photoplethysmography-based vital signs monitoring with B-Secur’s ECG analytics, we are enabling a new class of multimodal sensing solutions that deliver clinically relevant insights,” said Josef Hayoz, Senior Manager Medtech at CSEM. This collaboration leverages CSEM’s 25 years of leadership in vital signs monitoring and B-Secur’s HeartKey® software, which has already received multiple FDA 510(k) clearances for its ECG processing and arrhythmia analysis.

Navigating a Booming and Competitive Market

The timing for such an integrated solution is strategic. The global market for wearable healthcare devices is projected to surge from approximately $45 billion in 2025 to nearly $76 billion by 2030, with clinical-grade cardiac monitoring being a primary engine of that growth. This demand is fueled by an aging population, a rising prevalence of chronic diseases, and a societal shift towards proactive, preventative health management.

Of course, B-Secur and CSEM are not entering an empty arena. Tech giants like Apple, Fitbit (owned by Google), and Samsung have already integrated FDA-cleared ECG functionalities into their flagship watches, validating the consumer appetite for advanced health features. However, the B-Secur and CSEM collaboration isn’t aimed at competing with these giants directly. Instead, it serves as a crucial enabler for the rest of the industry.

Their offering is a turnkey solution for the myriad of other device manufacturers—from specialized medical companies to consumer electronics brands—looking to enter the clinical-grade wearable space. Developing these complex biosensing capabilities and navigating the labyrinthine regulatory approval process in-house can take years and cost millions. This partnership offers a shortcut, providing pre-validated, FDA-cleared components and end-to-end regulatory support. This dramatically lowers the barrier to entry, reduces R&D costs, and accelerates time-to-market, allowing more players to innovate in areas like remote patient monitoring and chronic disease management.

From Data Points to Diagnoses: The Real-World Impact

For patients and healthcare providers, the implications of truly reliable wearable data are profound. The ability to accurately detect transient arrhythmias, which may not appear during a brief visit to the doctor's office, can lead to earlier diagnosis and life-saving interventions. For individuals managing chronic cardiovascular conditions, a device armed with this technology offers a continuous, non-invasive window into their health, empowering them to take a more active role in their care.

The key advantage for clinicians is the promise of “clinically-validated” data. A common frustration among doctors is the flood of noisy, often inaccurate data and false alarms generated by consumer-grade wearables. By providing data that meets regulatory standards for accuracy, this new generation of devices can become a trusted source of information, seamlessly integrated into remote patient monitoring (RPM) programs.

Effective RPM has been shown to improve patient outcomes, reduce hospital readmissions, and lower healthcare costs—goals that align perfectly with the industry's move toward value-based care. When a physician can confidently rely on data streamed from a patient's wrist, it allows for more timely adjustments to treatment plans and a more proactive, preventative approach to medicine. The technology provides the foundation for a future where a patient's health is managed continuously, not just episodically.

The Path to Integration: Challenges and Solutions

While the promise is immense, the road to widespread adoption is not without its obstacles. Integrating clinical-grade sensors into a consumer-friendly form factor presents significant engineering challenges. Ensuring accuracy across diverse populations and under real-world conditions of movement and sweat requires incredibly sophisticated signal processing. B-Secur’s focus on noise-cancellation within its HeartKey® technology is a direct attempt to solve this core problem.

Beyond the hardware, device manufacturers must also contend with issues of battery life, data security, and interoperability. For the data to be clinically useful, it must flow securely and seamlessly into existing hospital infrastructures and Electronic Health Records (EHRs)—a long-standing challenge in digital health. The partnership provides the critical sensing and analytics engine, but the ultimate success of any device will depend on a holistic design that prioritizes user experience and data integration.

By providing a validated, modular solution, the B-Secur and CSEM partnership is laying critical groundwork. It empowers device makers to focus on these broader integration challenges, accelerating the development of a connected health ecosystem where the data from your wrist is not just interesting, but clinically actionable.